drugset

drugset / Trial / NCT00193245

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

NCT00193245 ↗

Phase 2 Completed 80 enrolled SCRI Development Innovations, LLC AstraZeneca · collab Aventis Pharmaceuticals · collab GlaxoSmithKline · collab

RandomizedCrossoverOpen-labelTreatment

Summary

In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.

Timeline

Start: 2000-11
Primary completion: 2005-10
Completion: 2009-01

Publications

Results Jones S, Thompson D, Barton J, Patton J, Shipley D, Greco FA, Spigel D, Infante J, Burris HA 3rd. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. Clin Lung Cancer. 2008 May;9(3):154-9. doi: 10.3816/CLC.2008.n.023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Topotecan	Small molecule	2 mg	Oral
Subject	Topotecan	Small molecule	2.5 mg	Oral

Indications